AC Immune Showcasing Precision Medicine Programs at AAIC 2023
July 03, 2023 07:00 ET
|
AC Immune SA
AC Immune Showcasing Precision Medicine Programs at AAIC 2023 Lausanne, Switzerland, July 3, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision...
AC Immune Holds Annual General Meeting of Shareholders
June 23, 2023 16:30 ET
|
AC Immune SA
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ:...
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
April 28, 2023 07:00 ET
|
AC Immune SA
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer’s disease...
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
April 24, 2023 07:30 ET
|
ProMIS Neurosciences Inc.
Lead therapeutic candidate for Alzheimer’s disease, PMN310, demonstrated selective binding and protection against toxic amyloid-beta oligomersPreclinical data support misfolded RACK1 as a potential...
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
April 05, 2023 07:00 ET
|
AC Immune SA
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease Webinar to take place on Tuesday, April 18, 2023, at 10:30 AM EDT / 4:30 PM CEST Lausanne,...
Astex and Cardiff University Medicines Discovery Institute Announce New Drug Discovery Collaboration on Neurodegenerative Diseases
February 13, 2023 04:00 ET
|
Astex Pharmaceuticals
CAMBRIDGE and CARDIFF, United Kingdom, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small...
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
February 07, 2023 07:00 ET
|
AC Immune SA
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer...
Zhittya Genesis Medicine - Parkinson’s Disease and Other Brain Disorders: Is FGF-1 a Novel Breakthrough Medical Treatment
October 25, 2022 10:00 ET
|
Zhittya Genesis Medicine Inc
Invitation to a Free Luncheon Presentation in Jeddah, Saudi Arabia, on Monday, October 31, 2022, at 1:00 pm (13:00) View Preliminary Human Data after 30 Days Treatment of Parkinson’s Disease Patients...
With 7.2% CAGR, Neurodegenerative Diseases Drugs Market Size to Surpass Around USD 62,786.2 Million by 2028
June 29, 2022 04:30 ET
|
Fortune Business Insights
Pune, India, June 29, 2022 (GLOBE NEWSWIRE) -- The global neurodegenerative diseases drugs market is likely to gain traction from the rising incidence of neurodegenerative diseases worldwide. Such...
Zhittya Genesis Medicine announces: Free Zoom Webinar: Parkinson’s Disease Sufferers Motor Skills Improve by 50% After Medical Research Study
June 21, 2022 10:00 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, June 21, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on June 23, 2022 at 3:00 PM Pacific Time...